Food Allergy Market to Reach USD 13.63 Billion by 2032 | CAGR 8.12% | North America Leads with 38% Share | Key Players: Astellas Pharma, Aimmune Therapeutics, Meridian Medical Technologies, ALK-Abelló

Food Allergy Market Overview

The global food allergy market reached US$ 7.30 billion in 2024 and is projected to grow to US$ 13.63 billion by 2032, expanding at a CAGR of 8.12% during the forecast period 2025-2032. The market growth is driven by the rising prevalence of food allergies, growing consumer awareness, and increasing demand for accurate diagnostics and effective therapeutic solutions.

Food allergies affect millions globally, with significant healthcare and social implications. In the United States, approximately 33 million individuals suffer from food allergies, resulting in around 3.4 million emergency visits annually due to severe allergic reactions. In the United Kingdom, the Food Standards Agency reports that 6% of adults have clinically confirmed food allergies, highlighting the growing need for preventive, diagnostic, and management solutions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/food-allergy-market?Juli

Recent Developments:

✅ October 2025: DBV Technologies reported strong Phase III clinical results for its Viaskin Peanut allergy patch in children aged 4-7, with nearly half of treated patients showing significant desensitization plans are underway to file for FDA approval in early 2026.

✅ March 2025: The U.S. FDA approved NEFFY (epinephrine nasal spray) for treatment of Type I allergic reactions, including anaphylaxis, in children aged 4 years and older, expanding non‐injectable emergency options for food allergy management.

✅ July 2024: Stallergenes Greer received expanded FDA approval for Palforzia oral immunotherapy to treat peanut allergy in toddlers aged 1-3 years, broadening pediatric immunotherapy access.

✅ February 2025: Aquestive Therapeutics was granted U.S. patents for ANAPHYLM, its epinephrine sublingual film formulation, strengthening its intellectual property in emergency allergy treatment delivery.

✅ May 2025: Intrommune Therapeutics announced positive safety data from early clinical studies of its novel peanut allergy therapy, highlighting excellent tolerability and no severe systemic reactions.

Mergers & Acquisitions:

✅ November 2025: A leading global allergy therapeutics firm acquired a peanut allergy immunotherapy developer to expand its food allergy treatment portfolio and accelerate clinical commercialization.

✅ September 2025: A major specialty pharma company completed the acquisition of a biotech startup focused on epinephrine delivery technologies, strengthening its emergency treatment offerings for severe allergic reactions.

✅ July 2025: A large nutraceutical manufacturer acquired a functional food and supplement company with established allergen‐free nutrition lines to enhance its position in preventative food allergy management products.

✅ May 2025: An international contract research and biologics services provider acquired a clinical immunotherapy research firm specializing in food allergy desensitization, augmenting its R&D capabilities.

✅ February 2025: A healthcare conglomerate merged with a diagnostic solutions provider to co‐develop advanced food allergen detection and monitoring platforms for clinical and consumer use.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=food-allergy-market?Juli

Key Players:

• Astellas Pharma, Inc. - A global pharmaceutical company focused on innovative allergy therapeutics and immunotherapy solutions.

• Aimmune Therapeutics - Specializes in food allergy treatments, particularly peanut immunotherapy.

• Meridian Medical Technologies - Known for emergency allergy treatments, including epinephrine auto-injectors.

• ALK-Abelló Ltd - Develops allergy immunotherapy products and diagnostics for various food allergens.

• Medeca Pharma AB - Focused on novel formulations and allergy treatment research.

• bioMérieux SA - Provides diagnostic solutions for food allergen detection and monitoring.

• Omega Diagnostics Group PLC - Offers diagnostic kits for allergy testing and monitoring.

• HYCOR Biomedical - Specializes in allergy diagnostic assays and immunoassay kits.

• HOB Biotech Group Corp Ltd. - Develops biotech solutions for allergen detection and treatment.

• Cambridge Allergy Ltd. - Focused on food allergy diagnostics and clinical testing technologies.

Market Segmentation:

➥By food source, peanuts account for the largest share with around 28%, followed by tree nuts at 20%, milk at 15%, shellfish at 12%, eggs at 10%, wheat at 7%, soy at 5%, and other emerging allergens at 3%.

➥By diagnosis, skin prick tests dominate with approximately 40% of the market, followed by blood-based tests (IgE) at 35%, component-resolved diagnostics at 15%, and molecular diagnostic tools at 10%. In terms of treatment, emergency interventions such as epinephrine auto-injectors hold the largest share at 45%, oral immunotherapy (OIT) accounts for 25%, sublingual immunotherapy (SLIT) at 15%, allergen avoidance strategies at 10%, and novel therapies under development at 5%.

➥By distribution channel, hospitals and clinics contribute 35%, pharmacies and drugstores 30%, specialty allergy centers 20%, and online retail platforms 15%, reflecting the increasing adoption of digital healthcare solutions and convenience-based purchasing trends.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/food-allergy-market?Juli

Market Dynamics:

The global food allergy market is being significantly driven by the rising demand for allergen-free products. Approximately 500 million individuals worldwide, including around 85 million in the U.S., actively avoid allergens in food and beverages, highlighting substantial growth potential for the market. Over the past two decades, food allergy incidence among American youths has increased roughly fourfold, outpacing population growth. This trend is not limited to the U.S.; food allergies are rising globally, particularly among young children in both developed and developing nations. Consumers affected by allergies or purchasing for someone who is often face stress while navigating grocery aisles to avoid allergens, frequently spending considerable time analyzing product labels or even avoiding entire product categories. Many consumers are willing to pay a premium for allergen-free products, showing preference for smaller, allergy-focused brands over larger firms and demonstrating openness to innovative alternatives. In the U.S., spending on allergen-free supermarket products reaches nearly US$ 19 billion annually, and this figure is expected to continue growing, reflecting a strong expansion opportunity for the food allergy sector.

However, the high cost of diagnosis and management of food allergies poses a notable restraint on market growth. Annual incremental healthcare costs per individual range from US$ 330-435, with anaphylaxis treatment adding approximately US$ 865 and adrenaline auto-injectors another US$ 510. In the U.K., these combined expenses total roughly US$ 44-58 million annually. Such financial burdens can limit access to timely diagnosis and consistent treatment, particularly for individuals without adequate insurance or resources. The high cost also constrains the adoption of preventative strategies, advanced diagnostic procedures, and innovative therapies, thereby limiting market accessibility and slowing the growth of food allergy diagnostics, therapeutics, and allergen-free product demand.

Regional Insights:

North America dominates the global food allergy market with an estimated 38% share in 2024, driven by high prevalence of food allergies, strong awareness of allergen-free products, advanced healthcare infrastructure, and higher disposable incomes. The U.S. accounts for the majority of this share, supported by widespread adoption of allergen labeling, strict regulations, and robust availability of diagnostic and therapeutic solutions.

Europe holds the second-largest share at approximately 28%, fueled by rising awareness of food allergies, strict regulatory frameworks for allergen labeling, and increasing availability of allergen-free and therapeutic products. Countries such as the U.K., Germany, and France lead in adoption due to strong healthcare systems, preventive care measures, and consumer willingness to spend on high-quality allergen-free products.

Asia-Pacific is expected to register significant growth, contributing around 20% of the market in 2024, driven by rapid urbanization, rising disposable income, and increasing awareness about food allergens. Japan, China, and Australia are emerging as key markets, with consumers showing growing interest in allergen-free diets and products.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.